Leronablim is in clinical development to treat experienced adult HIV-1 patients infected with C-C chemokine receptor type 5 (CCR5)-tropic virus. Antiretroviral medicines are used to treat HIV. However, poor adherence and the subsequent development of drug resistance is one reason why HIV treatment can fail and therefore requires more treatment options.
Leronlimab is an antibody that targets a protein displayed on the surface of HIV (human immunodeficiency virus) treatment. Leronlimab has a unique mechanism of action by binding to the CCR5 protein with high affinity, and ultimately inhibiting HIV entry into CD4 cells. It is administered via subcutaneous (SC) injection. Leronalimab has been shown to be effective safe and effective compared to the standard of care. If licensed, leronlimab will offer an additional treatment option for treatment-experienced adult HIV-1 patients infected with CCR5-tropic virus, who currently have no well-tolerated therapies available.